JC10 Rec'd PCT/PTO 18 JUL 2005

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no pers	sons are required to res	Application Number		10/531,002
TRANSMITT	AL	Filing Date		April 12, 2005
FORM		First Named Invento	or	Stefan K. Lipinski
		Art Unit	•	N/A
(to be used for all correspondence after	r initial filing)	Examiner Name		Not Yet Assigned
Total Number of Pages in This Submiss	sion	Attorney Docket Nu	mber	66221-0042
EN	ICLOSURES	(Check all that a	pply)	
Fee Transmittal Form	Drawing(s)			After Allowance Communication to TC
Fee Attached	Licensing-rel	ated Papers		Appeal Communication to Board of Appeals and Interferences
Amendment/Reply	Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final	Petition to Co			Proprietary Information
Affidavits/declaration(s)		rney, Revocation rrespondence Address		Status Letter
Extension of Time Request	Terminal Disclaimer		Other Enclosure(s) (please Identify below):	
Express Abandonment Request	Request for Relatio		PTO Form SB/08 Copies of articles & non-U.S.	
X Information Disclosure Statement	I I ICD Number of CD(c)			eferences Return Receipt Postcard
Certified Copy of Priority Document(s)	Landso	ape Table on CD		
Reply to Missing Parts/ Incomplete Application	Remarks			
Reply to Missing Parts under 37 CFR 1.52 or 1.53				
5, 6, W. W 6, W. W				
		ANT, ATTORNEY,	OR A	GENT
Firm Name RADER, FISHMAN	.C			
Signature	V			
Printed name James F. Kamp	11			
Date July 15, 2005		Reg. N	o. 4	1,882
<u> </u>		· · · · · · · · · · · · · · · · · · ·		

Transmittal I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment Commission Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. (Wendy A. Balabon) Dated: July 15, 2005 Signature: _

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Box 1450, Alexandria, VA MS Amendment, Commissioner for Patents, P.Q 22313-1450, on the date shown below,

Dated: July 15, 2005

Signature: A. Balabon) Docket No.: 66221-0042

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Stefan K. Lipinski et al.

Application No.: 10/531,002

Confirmation No.: @@@

Filed: April 12, 2005

Art Unit: N/A

Examiner: Not Yet Assigned

IMPROVED IMMUNOTHERAPY

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

For:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each non-U.S. reference and article on the PTO/SB/08 is attached. Under the provisions of 37 CFR 1.98(d), a copy of the U.S. references listed on the attached form PTO-1449 are not required to be provided herewith and therefore are not submitted herewith.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any

Application No.: 10/531,002 Docket No.: 66221-0042

patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-0013, under Order No. 66221-0042. A duplicate copy of this paper is enclosed.

By_

Dated: July 15, 2005

Respectfully submitted,

James F Kamp

Registration No.: 41,882

RADER, FISHMAN & GRAUER PLLC

39533 Woodward Avenue

Suite 140

Bloomfield Hills, Michigan 48304

(248) 594-0656

Attorney for Applicant

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/531,002

Attorney Docket No.: 66221-0042

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

> MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	July 15, 2005
	Date

Dendy				
Signa	ature			
Wendy A.	Balabon			
Typed or printed name of print	person signing Certificate			
(248) 594-0615				
Registration Number, if applicable	Telephone Number			

Note:

Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (14 References) (2 pages) Information Disclosure Statement 1 Copy of each article (8) and each foreign reference (4) PCT International Search Report (6 pages)

Transmittal

Return Receipt Postcard

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
				Application Number	10/531,002
11	VEORMATION	1 DI	SCLOSURE	Filing Date	April 12, 2005
l s	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Stefan K. Lipinski
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	66221-0042

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
-	AA	US-5,830,464-A	11-03-1998	Pramod K. Srivastava		
	AB	US-5,182,109-A	01-26-1993	Shinichi Tamura et al.		
l						

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,			
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶		
1	ВА	WO-96/05866-A2	02-29-1996	Thomas Blankenstein; Max Delbrueck Centrum		1		
	BB	WO-01/64739-A1	09-07-2001	Cobra Therapeutics Ltd.				
	BC	WO- 01/35810-A2	05-25-2001	Dana-Farber Cancer Institute, Inc.				
	BD	WO- 98/17799-A1	04-30-1998	The Trustees Of The University of Pennsylvania				
	BE	WO- 98/17799-A1 Corrected Version	04-30-1998	The Trustees Of The University of Pennsylvania				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	PCT/GB International Search Report for PCT/GB 03/04388, 6 pages.	
	СВ	Q.K. Rahman et al, "Breaking the Non-Responsiveness of C57BL/6 Mice to the Malarial Antigen EB200 - The Role of Carrier and Adjuvant Molecules," Scandinavian Journal of Immunology, vol. 58, no. 4, October 2003, pages 395-403, XP-002272656.	
	CC	Database Biosis 'Online! Biosciences Information Service, Philadelphia, PA, US; Shengwu Huazue Yu Shengwu Wuli Xuebao, May 2001; Li Ming_Feng et al: "A Candidate Oral Vaccine to Helicobacter pylori: Fusion protein of HspA and CtxB"; Database accession no. prev200100290633, XP-002272812	
	CD	A. Hakim Djeha et al., "Expression of <i>Escherichia coli</i> B Nitroreductase in Established Human Tumor Xenografts in Mice Results in Potent Antitumoral and Bystander Effects upon Systemic Administration of the Prodrug CB1954," Cancer Gene Therapy, vol. 7, no. 5, May 2000, pages 721-731, XP-001015218	
	CE	Nathalie E. Blachere et al., "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy, Raven Press, New York, NY, vol. 14, no. 4, 1993, pages 352-356, XP-000973693	
	CF	Xu Guang et al., "Strategies for Enzyme/Prodrug Cancer Therapy," Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. US, November, 2001, vol. 7, no. 11, pages 3314-3324, XP-002272658.	

Examiner	Date	
Signature	Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
333311131311111111111111111111111111111				Application Number	10/531,002
INFORMATION DISCLOSURE				Filing Date	April 12, 2005
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Stefan K. Lipinski
				Art Unit	N/A
(Use as many sheets as necessary)		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	66221-0042

C	G Jane I. Grove et al., "Virus-Directed Enzyme Prodrug Therapy Using CB1954," Anti-Cancer Drug Design, Basingstoke, GB, vol. 14, no. 6, December 1999, pages 461-472, XP-009003925.
CI	H Pramod K. Srivastava et al., "Heat Shock Protein-Peptide Complexes In Cancer Immunotherapy," Current Opinion in Immunology, Current Biology Ltd., London, GB, vol. 6, no. 5, 1994, pages 728-732, XP-002037578.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.